APO AI-promotor polymorphism influences baseline HDL-cholesterol and apolipoprotein AI concentration in healthy men

• Autorzy: Wlodarczyk M. , Nowicka G.

Warianty tytułu

PL

Wpływ polimorfizmu w rejonie promotora genu APO AI na stężenie HDL cholesterolu i apolipoproteiny AI u zdrowych mężczyzn

• Języki publikacji: EN

Abstrakty

EN

Introduction. Lowlevels of high-density lipoprotein (HDL) cholesterol is a risk factor for coronary artery disease. Besides lifestyle, some gene polymorphisms areknown to be related to the individual HDL-cholesterol concentration. Aim. An apolipoprotein AI gene promoterpolymorphism, related to an adenine (A) to guanine (G) transition 75 base pairs upstream from the transcription initiation site, was studied in the group of healthy men. Methods. Genotyping was performed by polymerase chain reaction method with MspI restriction enzyme. Lipid profile was determined by routine biochemical measurements and apolipoprotein AI concentration was obtain by an immunotubidymetric method. Results. Frequency of the rare A allele was 16% and in the study group only one case of the AA genotype was found, whereas GG variants was observed in 23 participants (68%). Statistically significant differences were noted in HDL concentrations between A allele carriers and GG homozygotes: 56 ± 12 mg/dL vs 46 ± 12 mg/dL, respectively. GG males had also about 20 mg/dL lower apolipoprotein AI levels and about 17 mg/dL higher triglyceride levels. Conclusions. In the studied men of Polish origin the A allele was associated with higher HDL-cholesterol and apolipoprotein AI levels compared to GG homozygotes.

PL

Wstęp. Niski poziom lipoprotein o wysokiej gęstości jest czynnikiem ryzyka choroby wieńcowej. Poza czynnikami związanymi ze stylem życia, również niektóre polimorfizmy genetyczne mogą wpływać na indywidualne stężenie cholesterolu HDL. Cel. Celem pracy było określenie czy polimorfizm 75G/A promotora w genie apolipoproteiny AI determinuje poziom HDL-cholesterolu i apolipoproteiny AI w grupie zdrowych mężczyzn. Metody. Genotypowanie przeprowadzono metodą polimerazowej reakcji łańcuchowej (PCR) z enzymem restrykcyjnym Mspl. Profil lipidowy określono za pomocą rutynowych pomiarów biochemicznych i zaś do oceny stężenia apolipoproteiny AI wykorzystano metodę immunotubidymetryczą. Wyniki. W badanej grupie częstość występowania rzadkiego allelu A wynosiła 16%. Stwierdzono tylko jeden przypadek genotypu AA, natomiast wariant GG obserwowano u 23 mężczyzn (68%). Odnotowano statystycznie istotne różnice w stężeniu HDL między grupą badanych z allelem A, a grupą homozygot GG: 56 ± 12 mg/dL vs 46 ± 12 mg/dl. Mężczyźni z genotypem GG mieli także o 20 mg/dL niższy poziom apolipoproteiny AI i o około 17 mg/dL wyższy poziom triglicerydów. Wnioski. W badanej grupie mężczyzn polskiego pochodzenia allel A był związany z wyższym stężeniem cholesterolu HDL oraz apolipoproteiny AI w porównaniu do grupy mężczyzn o układzie homozygotycznym GG.

Słowa kluczowe

EN

human disease; disease risk; lipoprotein; coronary artery disease; gene polymorphism; HDL-cholesterol; apolipoprotein A-I; concentration; polymerase chain reaction; healthy man; man

• Wydawca: -
• Czasopismo: Żywienie Człowieka i Metabolizm
• Rocznik: 2012
• Tom: 39
• Numer: 2
• Opis fizyczny: p.85-91,ref.

Twórcy

autor

Wlodarczyk M.

• Department of Nutrigenomics, national Food and Nutrition Institute, Warsaw, Poland

autor

Nowicka G.

• Department of Pharmacogenomics, Warsaw Medical University, Warsaw, Poland

Bibliografia

• 1. Gotto A.M. Jr, Brinton E.A.: Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. J. Am. Coll. Cardiol., 2004, 3, 43, 717-724.
• 2. McGrowder D., Riley C., Morrison E.Y., Gordon L.: The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer. Cholesterol, 2011, 496925.
• 3. Barter R, Kastelein J., Nunn A., et al.: High density lipoproteins (HDLs) and atherosclerosis; the unanswered questions. Atherosclerosis, 2003, 168,.2,.195-211.
• 4. Shah P.K., Kaul S., Nilsson J., et al.: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation, 2001, 13, 104, 2498-2502.
• 5. Skinner E.R.: High-density lipoprotein subclasses. Curr. Opin. Lipidol., 1994, 5,3, 241- 247.
• 6. Karathanasis S.K.: Apolipoprotein multigene family: tandem organization of human apolipoprotein AI, C-III and AIV genes. Proc. Natl. Acad. Sci. USA, 1985, 82, 6374-6378.
• 7. Ordovas J.M., Civeira F., Genest J.G., et al.: Restriction fragment length polymorphisms of the apolipoprotein Al, C-III, AIV gene locus: relationships with lipids, apolipoproteins, and premature coronary artery disease. Atherosclerosis 1991, 87, 75-86.
• 8. Assmann G., von Eckardstein A., Funke H.: High density lipoproteins, reverse transport of cholesterol and coronary artery disease. Insights from mutations. Circulation 1993, 87, III28-34.
• 9. Jeenah M., Kessling A., Miller N., Humphries S.E.: G to A substitution in the promoter region of the apolipoprotein Al gene is associated with elevated serum apolipoprotein Al and high density lipoprotein cholesterol concentrations. Mol. Biol. Med., 1990, 7, 233-241.
• 10. Sigurdsson G. Jr., Gudnason V, Sigurdsson G., Humphries S.E.: Interaction between a polymorphism of the apo Al promoter region and smoking determines plasma levels of HDL and apo Al. Arterioscler. Thromb., 1992, 12, 1017-1022
• 11. Lahoz C., Peña R., Mostaza J.M., et al.: RAP Study Group. Apo Al promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 2003, 168, 2, 289-295.
• 12. Paul-Hayase H., Rosseneu M., Van Bervliet J.P.: Polymorphism in the apolipoprotein (apo) AI-CIII-AIV gene cluster: detection of genetic variation determining plasma apo Al, apo C-III and apo AIV concentrations. Hum. Genet., 1992, 88, 439-446.
• 13. Pagani F, Giudici G.A.,' Baralle F.E., Vergani C.: Association of a polymorphism in the apo Al gene promoter with hyperalphalipoproteinemia. Eur. J. Epidemiol., 1992, 8(Suppl 1), 54-58.
• 14. Civeira F, Pocovi M., Cenarro A., et al.: Adenine for guanine substitution -78 base pairs 5’ to the apolipoprotein (APO) A-I gene: relation with high density lipoprotein cholesterol and APO A-I concentrations. Clin. Genet., 1993, 44, 307-312.
• 15. Barre D.E., Guerra R., Verstraete R., et al.: Genetic analysis of a polymorphism in the human apolipoprotein Al gene promoter: effect on plasma HDL-cholesterol levels. J. Lipid Res., 1994, 35, 1292-1296.
• 16. Minnich A., DeLangavant G., Lavigne J., et al.: G.A substitution at position _75 of the apolipoprotein Al gene promoter. Evidence against a direct effect on HDL cholesterol levels. Arterioscler. Thromb. Vase. Biol., 1995, 15, 1740-1745.
• 17. Xu C-F, Angelico F, Del Ben M., Humphries S.E.: Role of genetic variation at the apo AI-CIII-AIV gene cluster in determining plasma apo Al levels in boys and girls. Genet Epidemiol., 1993, 10, 113-122.
• 18. Smith J.D., Brinton E.A., Breslow J.L.: Polymorphism in the human apolipoprotein Al gene promoter region. Association of the minor allele with decreased production rate in vivo and promoter activity in vitro. J. Clin. Invest., 1992, 89, 1796-1800.
• 19. Pulkkinen A., Viitanen L., Kareinen A., et al.: MspI polymorphism at +83 bp in intron 1 of the human apolipoprotein Al gene is associated with elevated levels of HDL cholesterol and apolipoprotein Al in nondiabetic subjects but not in type 2 diabetic patients with coronary heart disease. Diabetes Care 2000 , 23, 791-795.
• 20. Barter P.J., Nicholls S., Rye K.A., et al.: Antiinflammatory properties of HDL. Circ. Res., 2004, 15, 95, 764-772.
• 21. Brewer H.B. Jr., Remaley A.T., Neufeld E.B., et al.: Regulation of plasma high-density lipoprotein levels by the ABCA1 transporter and the emerging role of high-density lipoprotein in the treatment of cardiovascular disease. Arterioscler. Thromb. Vase. Biol., 2004, 24, 1755-1760.
• 22. Tuteja R., Tuteja N., Meló C., et al.: Transcription efficiency of human apolipoprotein Al promoter varies with naturally occurring Ato G transition. FEBS Lett., 1992, 8, 304, 98-101.
• 23. Pagani F., Sidoli A., Giudici G.A., et al.: Human apolipoprotein AI gene promoter polymorphism: association with hyperalphalipoproteinemia. J. Lipid Res., 1990, 31, 1371-1377.
• 24. Contois J., McNamara J.R., Lammi-Keefe C., et al.: Reference intervals for plasma apolipoprotein A-l determined with a standardized commercial immunoturbidime- tric assay: results from the Framingham Offspring Study. Clin Chem., 1996, 42, 507-514.
• 25. O’Brien T., Nguyen T.T., Hallaway B.J., et al.: The role of lipoprotein AI and lipoprotein AI/ All in predicting coronary artery disease. Arterioscler Thromb Vase Biol., 1995,15, 228-231.
• 26. Luria M.H., Jacob J.E., Sapoznikov D., Gotsman M.S.: Cardiovascular risk factor clustering and ratio of total cholesterol to high-density lipoprotein cholesterol in angiographically documented coronary artery disease. Am J Cardiol., 1991, 67, 31-36.
• 27. Stampfer M.J., Sacks F.M., Salvini S., et al.: A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N. Engl. J. Med., 1991, 325, 373-381.
• 28. Leiviskà J., Sundvall J., Alfthan G., et al.: Apolipoprotein AI, apolipoprotein B, and apolipoprotein B/apoli- poprotein AI ratio: reference intervals compared with values in different pathophysiological conditions from the FINRISK 2007 study. Clin Chim Acta., 2011, 12, 412, 1146-1150.
• 29. Stasiakowska-Badura E., Kochmański M.: Lipid and carbohydrate disturbances in men with coronary artery disease according to age. Pol. Arch. Med. Wewn., 2006, 116, 955-964.
• 30. Langlois M.R., Blaton V.H.: Historical milestones in measurement of HDL-cholesterol: impact on clinical and laboratory practice. Clin. Chim. Acta., 2006, 23, 369, 168-178.
• 31. G. Walldius, Jungner I., Holme I., A.H., et al.: High apolipoprotein B, low apolipoprotein AI, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001, 358, 2026-2033.
• 32. Walldius G., Jungner I., Aastveit A.H., et al.: The apoB/apo AI ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk Clin. Chem. Lab. Med., 2004, 42, 1355-1363.
• 33. Marcovina S.M., Albers J.J., Henderson L.O., Hannon W.H.: International Federation of Clinical Chemistry standardization project for measurements of apolipoprotein AI and B: III. Comparability of apolipoprotein AI values by use of international reference material Clin. Chem., 1993, 39,773-781.
• 34. Wald N.J., Law M., Watt H.C., et al.: Apolipoproteins and ischemic heart disease: implications for screening. Lancet., 1994, 343, 75-79.
• 35. Lamarche B., Moorjani S., Lupien P.J., et al.: Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study. Circulation 1996, 1, 94, 3, 73-78.
• 36. Larson I.A., Ordovas J.M., Barnard J.R., et al.: Effects of apolipoprotein AI genetic variations on plasma apolipoprotein, serum lipoprotein and glucose levels. Clin Genet., 2002 , 61, 176-184.
• 37. Lahoz C., Peña R., Mostaza J.M., et al.: RAP Study Group. Apo AI promoter polymorphism influences basal HDL-cholesterol and its response to pravastatin therapy. Atherosclerosis 2003, 168, 289-295.
• 38. Do H.Q., Nazih H., Luc G., Arveiler D., et al.: Influence of cholesteryl ester transfer protein, peroxisome proliferator-activated receptor alpha, apolipoprotein E, and apolipoprotein AI polymorphisms on high-density lipoprotein cholesterol, apolipoprotein AI, lipoprotein AI, and lipoprotein AI: All concentrations: the Prospective Epidemiological Study of Myocardial Infarction study. Metabolism., 2009, 58, 283-289.
• 39. Mata P., López-Miranda J., Pocovi M., et al.: Human apolipoprotein AI gene promoter mutation influences plasma low density lipoprotein cholesterol response to dietary fat saturation. Atherosclerosis 1998, 37, 367-376.